The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Strong positive staining in tumour stroma of all carcinomas.
Among tumors, moderate to strong cytoplasmic and membranous immunoreactivity was observed in malignant melanomas and in some malignant gliomas, endometrial cancers and renal cancers. Other malignant tissues were in general negative.
Melanomas, lymphomas, renal, thyroid and endometrial cancers along with a few cases of gliomas, lung, ovarian and squamous cell carcinomas exhibited moderate to strong cytoplasmic and/or membranous positivity. Remaining cancer tissues were mainly negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
